此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Changes in Intraocular Pressure After Intravitreal Injection

2026年9月13日 更新者:Esraa Hussein Ali、Assiut University

Monitoring Changes in Intraocular Pressure After Intravitreal Injection

Intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections introduce additional fluid volume into the eye, which can cause an acute, transient elevation in intraocular pressure (IOP). The purpose of this prospective observational study is to evaluate the immediate and early changes in intraocular pressure following intravitreal anti-VEGF injections and to determine how rapidly pressure recovers toward baseline levels.

Adult participants scheduled to receive routine intravitreal anti-VEGF therapy for established clinical indications, such as diabetic macular edema, neovascular age-related macular degeneration, or retinal vein occlusion, will be enrolled. Intraocular pressure will be measured using an Icare rebound tonometer with single-use disposable probes before injection (baseline) and at 1 minute, 5 minutes, and 20 minutes post-injection. The study will also analyze whether factors such as refractive error, the number of prior injections, or the type of anti-VEGF drug administered affect the severity of post-injection pressure spikes and subsequent recovery.

研究概览

研究类型

观察性的

注册 (估计的)

50

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不适用

取样方法

非概率样本

研究人群

Adult patients attending the Ophthalmology Department at El Mabara Hospital in Assiut, Egypt, who are scheduled to receive routine intravitreal anti-VEGF injections for vitreoretinal conditions such as diabetic macular edema, neovascular age-related macular degeneration, or retinal vein occlusion.

描述

Inclusion Criteria:

  • Age 18 years or older.
  • Scheduled to receive an intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection for an established clinical indication (e.g., diabetic macular edema, neovascular age-related macular degeneration, or retinal vein occlusion).
  • Provision of written informed consent prior to enrollment.

Exclusion Criteria:

  • Known history of glaucoma or ocular hypertension.
  • History of previous glaucoma surgery.
  • Corneal diseases or ocular conditions that significantly interfere with accurate intraocular pressure measurement.
  • Inability to cooperate adequately during intraocular pressure measurement.
  • Refusal to participate or failure to provide informed consent.
  • Development of marked intraocular pressure elevation immediately after injection (IOP ≥ 40 mmHg) requiring anterior chamber paracentesis.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
Intravitreal Anti-VEGF Injection Cohort
Patients aged 18 years and older scheduled to receive an intravitreal anti-VEGF injection for established clinical indications, including diabetic macular edema, neovascular age-related macular degeneration, or retinal vein occlusion. Participants undergo baseline ophthalmic evaluation followed by intraocular pressure (IOP) monitoring at 1 minute, 5 minutes, and 20 minutes post-injection using an Icare rebound tonometer.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change from Baseline in Intraocular Pressure at 1 Minute
大体时间:Baseline and 1 minute post-injection
Intraocular pressure will be measured in mmHg using an Icare rebound tonometer with a single-use disposable probe to assess the acute post-injection pressure spike compared to baseline.
Baseline and 1 minute post-injection
Change from Baseline in Intraocular Pressure at 5 Minutes
大体时间:Baseline and 5 minutes post-injection
Intraocular pressure will be measured in mmHg using an Icare rebound tonometer with a single-use disposable probe to evaluate early post-injection pressure trends.
Baseline and 5 minutes post-injection
Change from Baseline in Intraocular Pressure at 20 Minutes
大体时间:Baseline and 20 minutes post-injection
Intraocular pressure will be measured in mmHg using an Icare rebound tonometer to assess the rate and extent of pressure recovery toward pre-injection baseline levels.
Baseline and 20 minutes post-injection

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年10月1日

初级完成 (估计的)

2027年10月1日

研究完成 (估计的)

2027年11月1日

研究注册日期

首次提交

2026年9月13日

首先提交符合 QC 标准的

2026年9月13日

首次发布 (实际的)

2026年9月17日

研究记录更新

最后更新发布 (实际的)

2026年9月17日

上次提交的符合 QC 标准的更新

2026年9月13日

最后验证

2026年9月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅